Bristol-Myers Squibb Compnay

Aaron Yamniuk

Ginger Chao Rakestraw

Stanley Richard Krystek, Jr

Mary Struthers

Akbar Nayeem

William R Ewing

Suzanne J Suchard

Andrew K Dilger

Steven Sheriff

Lumelle A Schneeweis

Jason Robert Pinckney

Christina Terragni

Joseph M Luettgen

Yongmi An

Kevin Kish

The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies

Antagonistic CD40 monoclonal antibodies and uses thereof

The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.

Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof

The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

Nucleic acids encoding antagonistic CD40 monoclonal antibodies

Growing community of inventors

Vancouver, Canada

Aaron Yamniuk